Nicox (OTCMKTS:NICXF) is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis. ZERVIATE is marketed in the United States through a partnership with Bausch + Lomb, following its FDA approval and U.S. launch in 2021. In parallel, Nicox is advancing NCX 470, a nitric oxide–donating derivative of latanoprost, through Phase III trials for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox is also developing NCX 4251, an anti-inflammatory prodrug in Phase II development for the treatment of dry eye disease.
Established in 1996 and headquartered in Sophia Antipolis, France, Nicox maintains a presence in North America and Europe through its U.S. subsidiary and regional partnerships. The company has entered licensing agreements with Innova Pharma for ex-US distribution of ZERVIATE in select Eastern European markets, and continues to explore further collaborations to extend its commercial reach. Nicox’s research and development operations leverage both internal expertise and external alliances to accelerate the discovery of novel ocular therapies.
Nicox is led by Chief Executive Officer Antoine Millon, under whose leadership the company has executed multiple clinical milestones and strategic partnerships. With a management team experienced in ophthalmology drug development and commercialization, Nicox is positioned to advance its portfolio of differentiated candidates toward regulatory approvals and market entry. The company’s ongoing focus remains on delivering therapies that improve patient outcomes and address global needs in eye care.
